ESR1 and uterine cancer: ERα-specific drugs, such as selective ER modulators (SERMs), selective ER degraders (SERDs), complete ER antagonists (CERANs), selective ER covalent antagonists (SERCAs), and proteolysis-targeting chimera (PROTAC) ER degraders, are used to counteract the effects of estrogens, especially in breast and uterus cancers, where this receptor triggers mainly proliferative signals [162].